Cosmesis and Breast-Related Quality of Life Outcomes After Intraoperative Radiation Therapy for Early Breast Cancer: A Substudy of the TARGIT-A Trial

Journal Article · Thu Sep 01 04:00:00 EDT 2016 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2016.04.024· OSTI ID:22648780

Corica, Tammy ^[1]; Nowak, Anna K. ^[2]; Saunders, Christobel M. ^[3]; Bulsara, Max ^[4]; Taylor, Mandy ^[5]; Vaidya, Jayant S. ^[6]; Baum, Michael ^[7]; Joseph, David J. ^[8]; Genesis Cancer Care, Western Australia ^[9]

---

1. Radiation Oncology Clinical Trials and Research Unit, Comprehensive Cancer Centre, Sir Charles Gairdner Hospital, Nedlands, Western Australia (Australia)
2. School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia (Australia)
3. School of Surgery, University of Western Australia, Crawley, Western Australia (Australia)
4. Institute for Health Research, University of Notre Dame, Fremantle, Western Australia (Australia)
5. Radiation Oncology, Comprehensive Cancer Centre, Sir Charles Gairdner Hospital Nedlands, Western Australia (Australia)
6. Department of Surgery, Royal Free Hospital, London (United Kingdom)
7. Clinical Trials Group, Division of Surgery and Interventional Science, University College London, London (United Kingdom)
8. School of Surgery, University of Western Australia, Western Australia (Australia)
9. Australia

Purpose: To report the first comprehensive investigation of patient-reported cosmesis and breast-related quality of life (QOL) outcomes comparing patients randomized to risk-adapted single-dose intraoperative radiation therapy (TARGIT-IORT) versus external beam radiation therapy (EBRT) on the TARGIT-A trial. Methods and Materials: Longitudinal cosmesis and QOL data were collected from a subset of TARGIT-A participants who received TARGIT-IORT as a separate procedure (postpathology). Patients completed a cosmetic assessment before radiation therapy and annually thereafter for at least 5 years. Patients also completed the combined European Organization for Research and Treatment of Cancer (EORTC) core questionnaire and Breast-Specific Module in addition to the Body Image after Breast Cancer Questionnaire at baseline and annually thereafter. The combined EORTC questionnaires were also collected 3, 6, and 9 months after wide local excision. Results: An Excellent–Good cosmetic result was scored more often than a Fair–Poor result for both treatment groups across all time points. The TARGIT-IORT patients reported better breast-related QOL than EBRT patients. Statistically and clinically significant differences were seen at month 6 and year 1, with EBRT patients having moderately worse breast symptoms (a statistically significant difference of more than 10 in a 100-point scale) than TARGIT-IORT patients at these time points. Conclusion: Patients treated with TARGIT-IORT on the TARGIT-A trial have similar self-reported cosmetic outcome but better breast-related QOL outcomes than patients treated with EBRT. This important evidence can facilitate the treatment decision-making process for patients who have early breast cancer suitable for breast-conserving surgery and inform their clinicians.

• OSTI ID: 22648780
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 96; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
DECISION MAKING
EXTERNAL BEAM RADIATION THERAPY
MAMMARY GLANDS
NEOPLASMS
PATIENTS
RADIATION HAZARDS
STANDARD OF LIVING